deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 4-arm NCT00565851

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)

Sponsor: NRG Oncology

Conditions Clear Cell Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Mucinous Adenocarcinoma Ovarian Brenner Tumor Ovarian Clear Cell Adenocarcinofibroma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Primary Peritoneal Clear Cell Adenocarcinoma Primary Peritoneal Endometrioid Adenocarcinoma Primary Peritoneal Serous Adenocarcinoma Primary Peritoneal Transitional Cell Carcinoma Primary Peritoneal Undifferentiated Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Undifferentiated Carcinoma
Interventions Bevacizumab Carboplatin Docetaxel Gemcitabine Hydrochloride Laboratory Biomarker Analysis Paclitaxel Quality-of-Life Assessment
Updated 51 times since 2017 Last updated: Dec 16, 2025 Started: Dec 6, 2007 Primary completion: Apr 30, 2019 Completion: Jan 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Clear Cell Adenocarcinoma and Fallopian Tube Clear Cell Adenocarcinoma and is currently ongoing. NRG Oncology leads this study, which shows 51 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Nov 2021 · 5 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2024 · 13 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 5 months · monthly snapshot

Change History

51 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Dec 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 46 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  3. May 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Dec 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  10. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  11. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2022 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  14. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  15. Nov 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  16. Jun 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  17. May 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  18. Mar 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  19. Feb 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  20. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  21. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  22. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  23. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  24. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  25. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  26. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  27. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  28. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  29. Apr 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  30. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  31. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  32. Oct 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  33. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  34. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  35. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  36. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  37. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  38. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  39. Oct 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE3

  40. Jul 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  41. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  42. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  43. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  44. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  45. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  46. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Abington, United States , Akron, United States , Albany, United States , Albuquerque, United States , Allentown, United States , Altamonte Springs, United States , Amarillo, United States , American Fork, United States , Anacortes, United States and 412 more locations